BioNTech AG of Germany has appointed Sean Marett, an industry veteran, as its chief operating officer. Mr Marett has more than 25 years of experience in licensing; mergers and acquisitions; and new product development with companies such as GlaxoSmithKline Plc, UCB SA and Evotec AG.
BioNTech is a spin-out of the Johannes-Gutenberg-Universität in Mainz and is researching and developing vaccine technologies against cancer.
BioNTech announced the appointment on 30 October 2012.
Copyright 2012 Evernow Publishing Ltd